GlycoEra raises $130m for IgG4-targeted protein degrader

From Yahoo Finance: 2025-05-28 07:11:00

Biotechnology company GlycoEra closed a $130m Series B financing round to advance its lead IgG4-targeted protein degrader. The investment will support the development of precision extracellular degraders for immunology and other indications. Novo Holdings led the financing, with contributions from new and current investors. GlycoEra’s platform targets a range of extracellular proteins, offering a natural process for protein degradation. The company’s lead programme, GE8820, aims to selectively degrade pathogenic IgG4 autoantibodies. CEO Ganesh Kaundinya plans to initiate first-in-human clinical trials later this year. GlycoEra added three new members to its board of directors. The company is based in Switzerland with additional offices and labs in the US.



Read more at Yahoo Finance: GlycoEra secures $130m to progress IgG4-targeted protein degrader